Haleon Expected to Report Strong Q4 Sales and Margin Growth Despite Weaker Cold Season
ByAinvest
Wednesday, Jan 21, 2026 11:00 am ET1min read
HLN--
Haleon is expected to report solid margin growth despite a weaker cold and flu season. Q4 organic sales growth is forecast at 3.1%, below consensus estimates, but the company's full-year growth is still expected to be around 3.2%. The more significant development is a 50 basis point improvement in operating margin to 22.8%, ahead of consensus expectations. Growth is led by Asia-Pacific and Latin America, with North America in slight decline. Oral health is the star performer, while therapeutic skin health softens after last year's Eroxon launch.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet